E-mail: jurcek.tomas@fnbrno.cz
Odborné práce publikované na Linkos.cz
Přehled odborných textů publikovaných autorem na portálu Linkos.cz. Jsou zde uvedeny knihy a brožury, články v Klinické onkologii, tuzemská abstrakta z databáze abstrakt a další texty. Rejstřík není v žádném případě úplným autorským rejstříkem, protože jsou zde uvedeny pouze texty zveřejněné na portálu Linkos.cz.
Publikovaná abstrakta
- AN ATYPICAL JUNCTION OF BCR-ABL GENE AS MOLECULAR MARKER FOR QUANTITATIVE MONITORING OF MINIMAL RESIDUAL DISEASE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML)
- CD26 ANTIGEN IS SPECIFIC FOR LEUKEMIC STEM CELLS IN CHRONIC MYELOID LEUKEMIA AND DISTINGUISHES PATIENT GROUPS WITH DIFFERENT RATIOS OF LEUKEMIC AND HEALTHY STEM CELL
- Cytogenetic Aberration Profile of Chronic Myeloid Leukemia and Its Dynamic Changes During Imatinib Therapy
- DASATINIB EFFICACY AND TOLERANCE IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS RESISTANT/INTOLERANT TO IMATINIB IN THE CONTEXT OF REAL CLINICAL PRACTICE MANAGEMENT
- DEFINING LOW AND UNDETECTABLE LEVELS OF DISEASE IN CHRONIC MYELOID LEUKAEMIA: PROGRESS TOWARDS STANDARDISATION IN EUROPE
- DETECTION OF AN ABERRANT FORM OF E13A2 BCR-ABL TRANSCRIPT CAUSING FAILURE OF MOLECULAR DIAGNOSTICS IN PATIENT WITH CHRONIC MYELOID LEUKEMIA (CML)
- EFFICACY AND SAFETY OF IMATINIB IN THE FIRST LINE CHRONIC MYELOID LEUKEMIA (CML) TREATMENT. AN ANALYSIS OF A COMPREHENSIVE POPULATION-BASED DATABASE
- CHRONIC MYELOID LEUKEMIA: IS THE REAL PROGNOSIS OF NEWLY DIAGNOSED PATIENTS REALLY SO GOOD?
- IMATINIB IN THE FIRST LINE CHRONIC MYELOID LEUKEMIA (CML) TREATMENT. CAN WE COMPARE THE REAL-LIFE DATA TO CLINICAL TRIAL RESULTS?
- IMATINIB IN THE FIRST-LINE CML TREATMENT: AN ANALYSIS OF A COMPREHENSIVE NON-COMMERCIAL DATABASE OF ALL CONSECUTIVE PATIENTS IN A DEFINED POPULATION
- IMPACT OF TREATMENT ADMINISTRATION ON SELECTION OF BCRABL1 KINASE DOMAIN MUTATIONS
- Minimal Residual Resistance In CML: Stable BCR-ABL Gene Expression at Levels 0.01–0.1% (IS) In the Consecutive Samples May Be Associated with BCR-ABL Mutation Development and MMoR Lost In a Small Number of Tyrosine Kinase Inhibitor Responders
- NEUROMUSCULAR TOXICITY OF TYROSINE KINASE INHIBITORS IN THE THERAPY OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA
- P53 Inactivation and Genomic Aberrations in Relation to Imatinib Resistance in Chronic Myeloid Leukemia
- SKIN ADVERSE EFFECTS OF TYROSINE KINASE INHIBITORS IN THE THERAPY OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA – SINGLE CENTRE EXPERIENCE
- T315I MUTATIONS ARE CLUSTERED WITH ADVANCED PHASES CONTRARY TO OTHER ABERRATIONS IN CML PATIENTS RESISTANT TO TKI THERAPY
- The Plateau of BCR-ABL Transcript Level =;>0.1% May Select CML Patients in Complete Cytogenetic Remission for Mutation Analysis.
- THE PROSPECTIVE ANALYSIS OF LOW LEVEL BCR-ABL1 T315I MUTATION IN THE CD34+ CELLS OF DE NOVO CML PATIENTS
- TREATMENT OF PHILADELPHIA-POSITIVE ADULT ACUTE LYMPHOBLASTIC LEUKEMIA IN REAL LIFE: EXPERIENCE OF ONE CENTRE
